Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2

The DOI matches its Crossref record.

Evaluation of the Effect of Aldehyde Oxidase Inhibitors on 6-Mercaptopurine Metabolism

Ueda, Hinata, Narumi, Katsuya, Furugen, Ayako, Okamoto, Keisuke, Saito, Yoshitaka, Kobayashi, Masaki·2025·Biological and Pharmaceutical Bulletin
DOI 10.1248/bpb.b25-00083
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1248/bpb.b25-00083

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 35

  1. 1) Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, Moser G. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology, 121, 1048–1053 (2001). · DOI
  2. 2) Eklund BI, Moberg M, Bergquist J, Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol. Pharmacol., 70, 747–754 (2006). · DOI
  3. 3) Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Klugmann T, Kruis W, Siegmund B, Helwig U, Weismüller J, Drabik A, Stallmach A. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases—a prospective study on incidence and severity. J. Crohns Colitis, 10, 61–68 (2016). · DOI
  4. 4) Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 24, 331–342 (2006). · DOI
  5. 5) Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology, 118, 705–713 (2000). · DOI
  6. 6) Gardiner SJ, Gearry RB, Burt MJ, Ding SL, Barclay ML. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur. J. Gastroenterol. Hepatol., 20, 1238–1242 (2008). · DOI
  7. 7) Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics, 11, 177–188 (2010). · DOI
  8. 8) Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, Haritunians T, Ye BD, Kim KJ, Park SH, Park SK, Yang DH, Dubinsky M, Lee I, McGovern DP, Liu J, Song K. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet., 46, 1017–1020 (2014). · DOI · Paper page
  9. 9) Broekman MM, Roelofs HM, Wong DR, Kerstholt M, Leijten A, Hoentjen F, Peters WH, Wanten GJ, de Jong DJ. Allopurinol and 5-aminosalicylic acid influence thiopurine-induced hepatotoxicity in vitro. Cell Biol. Toxicol., 31, 161–171 (2015). · DOI
  10. 10) Choughule KV, Barnaba C, Joswig-Jones CA, Jones JP. In vitro oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase. Drug Metab. Dispos., 42, 1334–1340 (2014). · DOI
  11. 11) Kurzawski M, Dziewanowski K, Safranow K, Drozdzik M. Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine. Ther. Drug Monit., 34, 266–274 (2012). · DOI
  12. 12) Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis CM, Ansari A, Duley J, Sanderson JD. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment. Pharmacol. Ther., 30, 375–384 (2009). · DOI
  13. 13) Ueda H, Narumi K, Asano S, Saito Y, Furugen A, Kobayashi M. Comparative study on the occurrence of adverse effects in the concomitant use of azathioprine and aldehyde oxidase inhibitors. Expert Opin. Drug Saf., 23, 89–97 (2024). · DOI
  14. 14) Kudo M, Sasaki T, Ishikawa M, Hirasawa N, Hiratsuka M. Kinetics of 6-thioxanthine metabolism by allelic variants of xanthine oxidase. Drug Metab. Pharmacokinet., 25, 361–366 (2010). · DOI
  15. 15) Itoh K, Masubuchi A, Sasaki T, Adachi M, Watanabe N, Nagata K, Yamazoe Y, Hiratsuka M, Mizugaki M, Tanaka Y. Genetic polymorphism of aldehyde oxidase in Donryu rats. Drug Metab. Dispos., 35, 734–739 (2007). · DOI
  16. 16) Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: inhibition by 239 drugs. J. Clin. Pharmacol., 44, 7–19 (2004). · DOI
  17. 17) Takaoka N, Sanoh S, Okuda K, Kotake Y, Sugahara G, Yanagi A, Ishida Y, Tateno C, Tayama Y, Sugihara K, Kitamura S, Kurosaki M, Terao M, Garattini E, Ohta S. Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug–drug interactions. Biochem. Pharmacol., 154, 28–38 (2018). · DOI
  18. 18) Barr JT, Jones JP. Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase. Drug Metab. Dispos., 41, 24–29 (2013). · DOI
  19. 19) Elion GB. Significance of azathioprine metabolites. Proc. R. Soc. Med., 65, 257–260 (1972). · DOI
  20. 20) Gardiner SJ, Gearry RB, Burt MJ, Chalmers-Watson T, Chapman BA, Ross AG, Stedman CA, Huelsen A, Barclay ML. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J. Gastroenterol. Hepatol., 26, 49–54 (2011). · DOI
  21. 21) Gawlik-Dziki U, Dziki D, Świeca M, Nowak R. Mechanism of action and interactions between xanthine oxidase inhibitors derived from natural sources of chlorogenic and ferulic acids. Food Chem., 225, 138–145 (2017). · DOI
  22. 22) Shi YW, Wang CP, Liu L, Liu YL, Wang X, Hong Y, Li Z, Kong LD. Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. Mol. Nutr. Food Res., 56, 1433–1444 (2012). · DOI
  23. 23) Kudo M, Moteki T, Sasaki T, Konno Y, Ujiie S, Onose A, Mizugaki M, Ishikawa M, Hiratsuka M. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet. Genomics, 18, 243–251 (2008). · DOI
  24. 24) Hall WW, Krenitsky TA. Aldehyde oxidase from rabbit liver: specificity toward purines and their analogs. Arch. Biochem. Biophys., 251, 36–46 (1986). · DOI
  25. 25) Rashidi MR, Beedham C, Smith JS, Davaran S. In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. Drug Metab. Pharmacokinet., 22, 299–306 (2007). · DOI
  26. 26) Terao M, Garattini E, Romão MJ, Leimkühler S. Evolution, expression, and substrate specificities of aldehyde oxidase enzymes in eukaryotes. J. Biol. Chem., 295, 5377–5389 (2020). · DOI
  27. 27) Basit A, Fan PW, Khojasteh SC, Murray BP, Smith BJ, Heyward S, Prasad B. Comparison of tissue abundance of non-cytochrome P450 drug-metabolizing enzymes by quantitative proteomics between humans and laboratory animal species. Drug Metab. Dispos., 50, 197–203 (2022). · DOI
  28. 28) Hanioka N, Saito K, Isobe T, Ohkawara S, Jinno H, Tanaka-Kagawa T. Favipiravir biotransformation in liver cytosol: species and sex differences in humans, monkeys, rats, and mice. Biopharm. Drug Dispos., 42, 218–225 (2021). · DOI
  29. 29) Uehara S, Yoneda N, Higuchi Y, Yamazaki H, Suemizu H. Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes. Drug Metab. Pharmacokinet., 41, 100419 (2021). · DOI
  30. 30) Crouch RD, Blobaum AL, Felts AS, Conn PJ, Lindsley CW. Species-specific involvement of aldehyde oxidase and xanthine oxidase in the metabolism of the pyrimidine-containing mGlu5-negative allosteric modulator VU0424238 (Auglurant). Drug Metab. Dispos., 45, 1245–1259 (2017). · DOI
  31. 31) Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T. Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab. Dispos., 32, 479–483 (2004). · DOI
  32. 32) Ban H, Andoh A, Imaeda H, Kobori A, Bamba S, Tsujikawa T, Sasaki M, Saito Y, Fujiyama Y. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J. Gastroenterol., 45, 1014–1021 (2010). · DOI
  33. 33) Jelovac M, Kotur N, Ristivojevic B, Pavlovic D, Spasovski V, Damjanov N, Pavlovic S, Zukic B. Can pharmacogenetic variants in TPMT, MTHFR and SLCO1B1 genes be used as potential markers of outcome prediction in systemic sclerosis patients? Int. J. Mol. Sci., 24, 8538 (2023). · DOI
  34. 34) Cao H, Pauff JM, Hille R. Substrate orientation and catalytic specificity in the action of xanthine oxidase: the sequential hydroxylation of hypoxanthine to uric acid. J. Biol. Chem., 285, 28044–28053 (2010). · DOI
  35. 35) Rowland K, Lennard L, Lilleyman JS. In vitro metabolism of 6-mercaptopurine by human liver cytosol. Xenobiotica, 29, 615–628 (1999). · DOI

Cited by

Metadata

Authors
Ueda, H., Narumi, K., Furugen, A., Okamoto, K., Saito, Y., & Kobayashi, M.
Venue
Biological and Pharmaceutical Bulletin
Publisher
Pharmaceutical Society of Japan
Published
2025-05-28
Volume
48
Issue
5
Pages
713-720
ISSN
  • 0918-6158
  • 1347-5215
DOI
10.1248/bpb.b25-00083
Cited by
2
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.